Natural products and herbal supplements have been explored as potential adjunctive therapies in Parkinson’s disease, although the evidence base remains predominantly preclinical and heterogeneous. Broad reviews describe multiple classes of compounds, including polyphenols, flavonoids, alkaloids, terpenoids, and amino acid–derived products, which demonstrate antioxidant, anti-inflammatory, anti-apoptotic, anti–α-synuclein aggregation, and mitochondrial-protective effects in experimental models, supporting biologic plausibility for neuroprotection. Selected agents with some degree of clinical investigation include Mucuna pruriens (a natural levodopa source), caffeine, green tea, and traditional formulations such as Jiawei-Liujunzi Tang, which have been associated with potential improvements in motor or nonmotor symptoms in small or limited studies; however, findings are inconsistent and not supported by robust, reproducible randomized data. Importantly, plant-derived compounds are generally positioned as adjuncts to levodopa-based therapy rather than alternatives, with theoretical potential to enhance dopaminergic response, reduce oxidative stress–related neuronal injury, or mitigate levodopa-associated complications such as motor fluctuations or dyskinesia, although these effects have not been definitively established in clinical trials. Data on pharmacokinetic or pharmacodynamic interactions with carbidopa–levodopa (Sinemet) are limited, with the exception of Mucuna pruriens, where variable levodopa content introduces potential for unpredictable dopaminergic exposure. Overall, while these agents demonstrate mechanistic rationale and emerging clinical signals, current evidence remains insufficient to support routine integration into standard Parkinson’s disease management. [1], [2], [3], [4]
A 2019 review describes complementary and alternative medicine use in Parkinson’s disease as common, with reported utilization rates ranging from approximately 61% to 76% in Asia compared to 26% to 40% in Western populations, while emphasizing that overall evidence quality remains limited and heterogeneous. For herbal therapies, Mucuna pruriens is highlighted as clinically relevant due to its natural levodopa content; in a randomized, double-blind crossover study (N=18), high-dose Mucuna demonstrated a significantly shorter latency to ON compared with levodopa/benserazide and a longer ON duration (221 vs 177 minutes; ~25% increase, p<0.001), with greater motor improvement at 90 and 180 minutes and fewer dyskinesias and adverse events (AEs) . These findings are consistent with earlier reports suggesting faster onset and prolonged motor response relative to standard formulations, likely reflecting higher levodopa exposure. However, marked variability in levodopa content of commercial Mucuna preparations, with analyses showing 6% to 141% deviation from labeled amounts, introduces substantial pharmacokinetic unpredictability and risk of under- or overexposure. Chinese herbal formulations were generally supported by low-quality evidence; one randomized trial of Jiawei-Liujunzi Tang (N=111) showed improvements in mood, cognition, and constipation but did not improve the primary endpoint (MDS-UPDRS Part I), while other agents such as Yokukansan were supported only by open-label data. Overall, the review indicates that while selected complementary therapies may demonstrate signals for benefit in specific domains, the evidence base remains inconsistent, methodologically limited, and insufficient to support routine integration into standard Parkinson’s disease management. [5], [6], [7]
Vitamin D has been evaluated as both a risk modifier and therapeutic adjunct in Parkinson’s disease. A meta-analysis of eight studies found that vitamin D insufficiency (<30 ng/mL) and deficiency (<20 ng/mL) were associated with increased Parkinson’s disease risk (odds ratio [OR] 1.77 and 2.55, respectively; both p<0.001; based on 3 studies each), while sunlight exposure ≥15 minutes per week was associated with reduced risk (OR 0.02; p<0.001; 3 studies); however, vitamin D supplementation increased serum 25-hydroxyvitamin D levels (SMD 1.79; p<0.001; 2 studies) without significantly improving motor function (MD –1.82; p=0.275; 2 studies). Dosing in the included randomized trials ranged from 1,200 IU/day to 50,000 IU/week (with additional 600 IU/day in one study), with no established dose–response relationship or demonstrated clinical benefit on motor outcomes. Mechanistically, vitamin D receptors are highly expressed in the substantia nigra and may influence dopaminergic neuron function through modulation of oxidative stress, neuroinflammation, calcium homeostasis, and neurotrophic signaling, providing biologic plausibility for a protective role . Despite these associations, clinical data remain inconsistent, and current evidence does not support a reproducible therapeutic effect of vitamin D supplementation on core Parkinson’s disease motor symptoms. See Table 1 for detailed study-level characteristics, dosing regimens, and quantitative efficacy outcomes (serum 25[OH]D changes and motor function measures) from the randomized controlled trials informing these findings. [8], [9]
Coenzyme Q10 (CoQ10), a mitochondrial cofactor with antioxidant properties, has been evaluated in Parkinson’s disease across randomized controlled trials (RCTs) with inconsistent clinical benefit. A meta-analysis of 8 RCTs (N=899) found no improvement in motor function, with no significant difference in UPDRS Part III scores compared with placebo (WMD 1.02; 95% CI –2.27 to 4.31; p=0.54), and similarly no significant effects on total UPDRS or subscores. Dosing across included trials varied widely, ranging from 300 mg/day to 2400 mg/day, including large-scale studies such as the QE3 trial (N≈600) evaluating 1200 mg/day and 2400 mg/day, which also demonstrated no clinical benefit despite adequate exposure. Notably, even high-dose CoQ10 (>1000 mg/day) did not show improvement in UPDRS outcomes compared with placebo. Earlier smaller trials suggested potential benefit at lower doses (e.g., 300 mg/day), but these findings were not reproduced in larger, higher-quality studies, contributing to overall heterogeneity. CoQ10 was consistently reported as safe and well tolerated, with no significant difference in AEs versus placebo. Overall, despite a strong mechanistic rationale related to mitochondrial dysfunction and oxidative stress, current evidence does not demonstrate a reproducible or dose-dependent therapeutic effect of CoQ10 on Parkinson’s disease motor outcomes. See Table 2 for study-level characteristics and corresponding quantitative UPDRS outcomes across individual RCTs included in the analysis. [10]
A 2022 systematic review of 81 studies evaluating interactions between Parkinson’s disease therapies and food or dietary supplements found that levodopa pharmacokinetics and clinical response are significantly influenced by dietary factors, with overall evidence limited and heterogeneous. High-protein diets were consistently associated with reduced levodopa effectiveness, likely due to competition with large neutral amino acids for intestinal and blood–brain transport, while ferrous sulfate supplementation demonstrated clinically relevant reductions in levodopa exposure, with decreases in AUC by 30–51% and Cmax by 47–55%, consistent with chelation and impaired absorption. In contrast, certain dietary components were associated with potential benefit, including vitamin C, dietary fiber, and coffee, which may enhance levodopa absorption or clinical response, and protein redistribution diets (lower daytime protein intake) may improve motor fluctuations. Additional interactions were less clinically significant or inconsistently supported; for example, aspartame increased phenylalanine levels but did not demonstrate measurable impact on motor outcomes. The review also highlights practical administration considerations, noting that immediate-release levodopa formulations are best taken on an empty stomach, whereas modified-release formulations are less affected by meals. Overall, while certain interactions such as protein intake and iron supplementation demonstrate clinically meaningful effects on levodopa exposure, the broader evidence base remains limited by study quality and heterogeneity, and data for other supplements are sparse. [11]